NCT03820037View on ClinicalTrials.gov

Relative Bioavailability and Bioequivalence of Opicapone

PHASE1CompletedINTERVENTIONAL
Enrollment

45

Participants

Timeline

Start Date

March 19, 2019

Primary Completion Date

June 9, 2019

Study Completion Date

June 9, 2019

Conditions
Parkinson Disease
Interventions
DRUG

Ongentys

single oral 50 mg (capsule containing 50 mg OPC) under fasting conditions

DRUG

BIA 9-1067 (test)

single oral 50 mg (capsule containing 50 mg OPC) under fasting conditions

Trial Locations (1)

LS2 9LH

Covance Clinical Research, Leeds

All Listed Sponsors
lead

Bial - Portela C S.A.

INDUSTRY

NCT03820037 - Relative Bioavailability and Bioequivalence of Opicapone | Biotech Hunter | Biotech Hunter